Court Overturns Federal Approval Of Dow Neonicotinoid | Chemical & Engineering News
Latest News
Web Date: September 10, 2015

Court Overturns Federal Approval Of Dow Neonicotinoid

Pesticides: EPA ordered to obtain more data on sulfoxaflor’s effects on bees
Department: Government & Policy | Collection: Sustainability
News Channels: Environmental SCENE
Keywords: sulfoxaflor, neonicotinoids, EPA, Dow Chemical, litigation

A federal court on Sept. 10 struck down EPA’s approval of the insecticide sulfoxaflor, citing the neonicotinoid’s possible risk to bees.

EPA’s 2013 decision to register sulfoxaflor “was based on flawed and limited data,” a three-judge panel of the U.S. Court of Appeals for the Ninth Circuit found.

“Given the precariousness of bee populations, leaving the EPA’s registration of sulfoxaflor in place risks more potential environmental harm” than does striking it down, the panel ruled. The court ordered the agency to obtain further data on the chemical’s effects on bees before deciding whether to reapprove Dow AgroSciences’ registration of sulfoxaflor, which has been sold under the trade names Transform and Closer.

Commercial beekeeping trade groups and individual professional beekeepers, represented by the environmental group Earthjustice, brought the suit against EPA shortly after the agency gave an unconditional green light to the chemical. “EPA’s pesticide application and review process must receive substantial scientific evidence as to the benefits of a pesticide, as well as the protection of the environment, especially the protection of pollinators,” says Michele Colopy, program director of one of the groups bringing the case, the Pollinator Stewardship Council.

Dow AgroSciences says it will complete additional studies to support the registration of sulfoxaflor and is weighing possible appeal of the court decision.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society
Comments
Bill (September 10, 2015 7:24 PM)
Finally a judge with some common sense.

Leave A Comment

*Required to comment